Clinical Milestone Achieved for BK002 !
We are pleased to announce that our clinical trial, Vitabiotic, has successfully reached the Last Patient Last Visit milestone.
This 14-week pilot study aimed to evaluate the efficacy and safety of our investigational product, BK002, in patients with Irritable Bowel Syndrome (IBS). With the promising interim analysis back in July, we are optimistic about the study results, expected by Q2 2025.
BK002 is coming closer to the market, bringing new hope for IBS patients. 🤩
A big thank you to our partners, Keyrus, our principal investigator Prof. Dr. Jan Tack, all the participating investigators, and everyone involved in making this trial a success!